AOD-9604 Dosage Guide: Chart, Protocol & Reconstitution (2026)

Community research plans often reference 300 to 500 mcg of AOD-9604 per day. Published human trials mainly studied oral and intravenous forms, so subcutaneous amounts come from community practice rather than an approved clinical protocol. With a 5 mg vial mixed with 3 mL of bacteriostatic water, 300 mcg equals about 18 units and 500 mcg equals about 30 units on a U-100 syringe.

AOD-9604 is a 16-amino-acid synthetic peptide. It matches the last 15 amino acids of human growth hormone, positions 177-191, with an extra tyrosine added at one end to help stabilize the molecule. It is also called HGH Fragment 176-191 or hexadecapeptide 177-191.

Researchers studied AOD-9604 to learn whether the fat-metabolism part of growth hormone could work without the muscle-building, blood-sugar, and IGF-1 effects of the full hormone. Most research has focused on fat metabolism, while separate animal studies have also looked at joints and cartilage.

Published human research with AOD-9604 used oral and intravenous routes. Community research plans now often model subcutaneous amounts, but no approved clinical protocol or published human pharmacokinetic study has established those subcutaneous amounts.

The table below summarizes a common community research-planning structure. It is not a dosing recommendation or a published clinical protocol.

The table below shows common educational calculations for a 5 mg vial. The syringe-unit amount changes based on how much bacteriostatic water is added to the vial.

Community research plans often use 300 to 500 mcg once per day. This range is not based on an approved subcutaneous human protocol. Published studies used different routes, including oral and intravenous administration, so the amounts cannot be directly transferred between routes.

A 5 mg AOD-9604 vial can be mixed with different amounts of bacteriostatic water. Adding more water lowers the concentration in each syringe unit but does not change the total amount in the vial. The best water volume for a calculation depends on the syringe-unit range being modeled.

Enter the vial size, bacteriostatic water amount, and target research amount to calculate the matching U-100 syringe units.

Open the AOD-9604 dosage and reconstitution calculator.

Published Phase 2 research lasted 12 or 24 weeks. Community research plans often use 8 to 16 weeks, but those shorter structures are anecdotal and are not controlled clinical protocols. Long-term evidence beyond 24 weeks is limited.

Read the full AOD-9604 cycle-length guide for a closer look at 8-, 12-, 16-, and 24-week timelines. You can also browse educational peptide cycle guides to compare other compounds and blends.

AOD-9604 was designed to copy the fat-metabolism end of human growth hormone without the rest of growth hormone's effects. In simple terms, growth hormone has a region near one end of its molecule that signals fat cells to release stored fat. AOD-9604 is a synthetic copy of that region, plus one extra amino acid for stability.

In animal research, AOD-9604 has done two main things. First, it stimulates lipolysis, which is the breakdown of stored fat into free fatty acids the body can use as fuel. Second, it appears to suppress lipogenesis, which is the storage of new fat. In Heffernan et al. 2001, AOD-9604 lost most of this fat-metabolism effect in mice that were genetically missing the beta-3 adrenergic receptor, suggesting that pathway carries part of the signal.

Importantly, AOD-9604 does not appear to bind to the growth hormone receptor itself in cell-binding studies. That is the proposed reason it does not raise IGF-1 levels or impair insulin sensitivity in animal work, in contrast to full-length growth hormone. The molecular target that AOD-9604 actually binds is still unidentified, which the FDA explicitly noted in its December 2024 evaluation.

A separate animal line of work has investigated AOD-9604 in joint research. Kwon and Park 2015 reported that intra-articular AOD-9604 injections, especially when combined with hyaluronic acid, improved cartilage scores and reduced lameness in a rabbit collagenase-induced osteoarthritis model. This is a single rabbit study, not human evidence.

AOD-9604 has been studied through more than one route, but doses cannot be directly converted between oral, intravenous, topical, nasal, and subcutaneous forms. Each route has different absorption and research limitations.

Community research plans often cite 300-500 mcg per day from a reconstituted vial. The FDA's 2024 review found no published human pharmacokinetic study that formally characterized the subcutaneous route, so these amounts are anecdotal rather than an approved clinical protocol.

Published trials used oral amounts from 0.25 mg to 30 mg per day. The largest Phase 2b trial used 0.25, 0.5, and 1 mg per day for 24 weeks, but it missed its main weight-loss endpoint. Oral bioavailability has not been clearly measured in humans.

Early human studies used single intravenous amounts of 25-400 mcg/kg. Those controlled study amounts describe a different route and cannot be converted into subcutaneous syringe units or oral amounts.

Topical and nasal forms appear in marketing, but the FDA review found no published human exposure data for transdermal or intranasal AOD-9604. There is no supported dose conversion from these routes to oral, intravenous, or subcutaneous research models.

AOD-9604 is a research compound with no FDA-approved indication for any patient population. The published record does not establish a human-use protocol.

Published human trials with AOD-9604 enrolled adults with obesity (BMI 30-45 kg/m^2), generally aged 18-65. Outside of that group, published safety data is essentially absent. The following populations have no published exposure data and would generally be excluded from research-context use:

- People who are pregnant, trying to become pregnant, or breastfeeding. - Anyone under 18. - People with active or recent cancer history (the trial record contains a small number of cancers in the 12-week oral arm; investigators considered them unrelated, but no long-term oncology safety data exists). - People with significant liver disease (the 9-month monkey toxicology study showed dose-dependent periportal vacuolation in hepatocytes that the FDA flagged as a possible safety signal). - People with poorly controlled bone-turnover conditions, until the dose-dependent osteocalcin changes seen in the 26-week rat study are better understood.

AOD-9604 is on the World Anti-Doping Agency Prohibited List under category S2.2 (peptide hormones, growth factors, related substances, and mimetics). Athletes subject to WADA, USADA, NCAA, or any sport-governing-body testing should not use AOD-9604 in any form. Metabolites can be detected in urine.

Specific drug-interaction studies with AOD-9604 have not been published. Any medication that affects glucose, lipid metabolism, growth hormone signaling, or beta-adrenergic activity could in theory interact, but evidence is absent. Discuss any active prescription with a qualified clinician before considering use.

AOD-9604 has one of the largest safety datasets of any research peptide in this category. Six controlled trials in approximately 900 participants are summarized in Stier et al. 2013, and FDA's December 2024 review lists the same trial set. The safety record is generally placebo-like, but several specific findings deserve attention.

Reported adverse events across the IV and oral trials included headache, fatigue, dizziness, nasopharyngitis, diarrhea, flatulence, increased appetite, nausea, and back pain. Most were mild or moderate. One report of severe chest tightness in the 50 mcg/kg IV arm was deemed possibly related. A small number of cancers (basal cell carcinoma, breast cancer, malignant melanoma, lipoma, squamous cell carcinoma) were reported during the 12-week oral METAOD005 trial; investigators considered them unrelated to study drug. Anti-AOD-9604 antibodies were not detected in tested participants.

FDA's 2024 review specifically flagged that no published human exposure data exists for the subcutaneous, transdermal, or intranasal routes that compounding pharmacies have offered. Injectable routes carry a particular concern for immunogenicity from peptide aggregation and impurities, and FDA noted the available certificates of analysis for AOD-9604 bulk drug substances did not consistently control for impurities, aggregates, or microbial limits.

Two animal findings reviewed by FDA are worth tracking even if they did not surface clinically. In a 26-week rat oral toxicity study, AOD-9604 produced dose-dependent changes in serum osteocalcin (a bone-turnover marker) at week 13, with the direction reversing by week 26. In a 9-month monkey oral toxicity study, all female monkeys in the high-dose group showed minimal-to-slight periportal hepatocyte vacuolation. FDA flagged both as potentially clinically relevant signals that warrant caution.

Because there is no FDA-approved AOD-9604 product, all material in circulation comes from research-supply or compounding sources. FDA noted that reviewed CoAs from suppliers did not consistently include controls for impurities, aggregates, or bacterial endotoxins. That makes supplier transparency, third-party HPLC purity confirmation, and lot-specific certificates non-negotiable for any research-context sourcing.

Setting realistic expectations is the most useful thing this section can do, because the published evidence is much more modest than typical clinic marketing.

The METAOD005 oral trial measured weight at 12 weeks. Reported weekly weight-loss differences over placebo were small (in the range of -0.06 to -0.15 kg/week, depending on dose). The METAOD006 (OPTIONS) oral Phase 2b trial measured weight at 12 and 24 weeks; the difference between AOD-9604 arms and placebo was not statistically significant at either point, and development was terminated.

If a clinician is overseeing research-context use, baseline and periodic checks that have appeared in published AOD-9604 monitoring include:

- Weight, waist circumference, and body composition. - Fasting glucose and a basic lipid panel (AOD-9604 did not raise glucose or worsen lipids in trials, but baseline confirmation is useful). - IGF-1 (trial data suggests no meaningful change; documentation can support that). - Liver enzymes if any preexisting liver concern, given the monkey toxicology signal. - Injection-site inspection for redness, induration, or lipohypertrophy.

Specific weight-loss targets, body-composition changes, or joint outcomes cannot be promised based on current evidence. Phase 2b primary endpoints failed in the largest published trial. Anyone planning research-context use should treat outcome reports cautiously and weigh the FDA-approved alternatives discussed in the comparisons section.

AOD-9604 is usually discussed in a fat-loss and metabolic research context. Lab monitoring is mainly pathway-based because routine clinical monitoring standards are not established for this peptide.

AOD-9604 is unusual among research peptides because it actually completed real Phase 1 and Phase 2 clinical trials. Six trials totaling roughly 900 participants are summarized in Stier et al. 2013 and re-evaluated in FDA's 2024 PCAC briefing.

As of June 2026, AOD-9604 is not FDA-approved for any therapeutic use. It is not the active ingredient in any FDA-approved drug product, and there is no United States Pharmacopeia (USP) monograph for either AOD-9604 (free base) or AOD-9604 acetate.

On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (free base) and AOD-9604 acetate against the 503A Bulks List. FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes.

AOD-9604 was previously nominated for inclusion under FDA's Category 2 list (substances proposed for compounding under research/evaluation). As of June 2026, AOD-9604 is listed as Nominated but Withdrawn, meaning it is no longer actively under Category 2 nomination.

AOD-9604 is on the World Anti-Doping Agency Prohibited List under section S2.2. The Australian Therapeutic Goods Administration added AOD-9604 to its Poisons Standard under performance and image-enhancing drugs (PIEDs), and possession without a legal prescription is restricted in Australia.

AOD-9604 was self-affirmed as Generally Recognized As Safe (GRAS) by an industry expert panel for limited food-ingredient use based on the Phase 1 and Phase 2 safety data. This GRAS designation does not imply FDA approval for therapeutic, drug, or compounded use, and it is sometimes misrepresented in marketing copy.

Search interest around AOD-9604 often surfaces alongside human growth hormone, HGH Fragment 176-191, and modern GLP-1 weight-management drugs. Each works through a different mechanism, and the evidence levels are very different.

The practical takeaway: AOD-9604 has a clean safety profile in trials but a failed Phase 2b efficacy endpoint. GLP-1 and GIP/GLP-1 drugs have strong Phase 3 efficacy and clear FDA-approved labels for weight management. They are not interchangeable, and the comparison is not symmetrical.

Related research peptides on Peptide Dosing Protocols that come up alongside AOD-9604: